Atlanta, GA - 
(NewMediaWire) - January 04, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.
Presentation Details:
Presenter: David Dodd, Chairman & CEO
Date/Time: January 9, 2023, 5:00 pm PST
Location: Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA
Website: https://informaconnect.com/biotech-showcase/registration-options/
A webcast of the presentation will be available at the following link: https://event.webcasts.com/starthere.jsp?ei=1590568&tp_key=ddac005afe
Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:
● Biotech Showcase partnering platform: https://informaconnect.com/biotech-showcase/
● Biotechnology Innovation Organization (BIO) partnering platform: https://www.bio.org/events/bio-partnering-jpm
● Direct outreach to the Company at info@geovax.com or to its Investor Relations at govx@cg.capital
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
Media Relations Contact:
Gina Cestari
6 Degrees
917-797-7904
gcestari@6degreespr.com
Investor Relations Contact:
Rich Cockrell
CG Capital
404-736-3838
govx@cg.capital
View the original release on www.newmediawire.com
